Ozempic Gastroparesis Attorney: Understanding the Statute of Limitations in New York

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Legal Concerns

For decades, general health and science communication has served as the foundation for public understanding of medical treatments and their potential side effects. This legacy framework emphasizes broad awareness of therapeutic benefits while acknowledging that all medications carry inherent risks. Within this context, the public has become increasingly informed about prescription drugs used for chronic conditions, including those for diabetes and weight management. As the landscape of pharmaceutical science evolves, so too does the need to translate general health principles into specific, actionable concerns for individuals who may have been exposed to particular medications. The transition from general health awareness to a focused occupational exposure concern begins with recognizing that certain patient populations face unique legal and medical considerations. In the case of glucagon-like peptide-1 receptor agonists such as Ozempic, widespread use has prompted scrutiny of associated adverse events, including gastroparesis—a condition affecting stomach muscle function. For individuals in New York who have taken Ozempic and subsequently developed gastroparesis, understanding the statute of limitations is critical. This legal timeframe dictates how long a person has to file a claim after discovering harm. The pivot from general health education to this specific exposure scenario underscores the importance of timely legal consultation, ensuring that affected individuals can seek recourse within the boundaries set by state law.

Pharmacological Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which can lead to gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has emerged as a significant concern. This section examines the clinical presentation, pharmacological links, and legal considerations for affected patients in New York. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests. In clinical trials of Ozempic, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which may include gastroparesis-like symptoms.

Mechanistic Evidence and Risk Context

The mechanistic pathway linking Ozempic to gastroparesis involves its action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and their activation slows gastric emptying. This effect is intended to reduce postprandial glucose excursions but can become pathological in susceptible individuals, leading to delayed gastric emptying and symptoms of gastroparesis. Postmarketing reports have highlighted rare cases of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for significant gastric retention, a hallmark of gastroparesis, even after standard fasting. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking Ozempic, including whether modifying preoperative fasting recommendations or temporarily discontinuing Ozempic could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This suggests that the drug's effect on gastric motility may persist and pose risks beyond typical gastrointestinal symptoms. Regarding the adequacy of warnings, the prescribing information for Ozempic includes gastrointestinal adverse reactions as common, but it does not specifically list gastroparesis as a distinct adverse reaction. The label notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not explicitly warn about gastroparesis as a potential complication. This gap may be relevant for patients who develop severe or persistent gastrointestinal symptoms that meet diagnostic criteria for gastroparesis. The absence of a specific warning could affect claims regarding failure to adequately inform patients and healthcare providers of this risk.

Statute of Limitations for Ozempic Gastroparesis Claims in New York

For patients in New York considering legal action, the statute of limitations for personal injury claims related to Ozempic-induced gastroparesis is generally three years from the date of injury or from when the injury was discovered or should have been discovered. This timeline is critical because gastroparesis may develop insidiously, with symptoms emerging weeks to months after starting Ozempic. The timeline between exposure and documented harm is variable: gastrointestinal adverse reactions often occur during dose escalation, but persistent symptoms may not be recognized as gastroparesis until diagnostic testing is performed. Patients should document the start date of Ozempic use, the onset of symptoms, and any medical evaluations confirming delayed gastric emptying. Attorney-related considerations include the need to establish a causal link between Ozempic and gastroparesis, which may require expert testimony on pharmacology and gastroenterology. The evidence from clinical trials showing higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo supports a plausible association, but individual cases must be evaluated for other potential causes. In summary, Ozempic is associated with a dose-dependent increase in gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The drug's mechanism of slowing gastric emptying provides a biological basis for this risk. Current warnings do not specifically address gastroparesis, which may be relevant for legal claims. Affected patients in New York should be aware of the three-year statute of limitations and the importance of documenting the timeline of exposure and harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for filing an Ozempic gastroparesis lawsuit in New York?

In New York, the statute of limitations for personal injury claims, including those related to Ozempic-induced gastroparesis, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. It is crucial to consult with an attorney promptly to ensure your claim is filed within this timeframe.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism to control blood sugar. In some individuals, this effect can become pathological, leading to delayed gastric emptying and symptoms of gastroparesis such as nausea, vomiting, and abdominal pain. Clinical trials have shown a dose-dependent increase in gastrointestinal adverse reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What evidence is needed to prove an Ozempic gastroparesis claim?

To prove a claim, you typically need documentation of Ozempic use, medical records confirming a gastroparesis diagnosis (e.g., gastric emptying scintigraphy), and expert testimony linking the drug to your condition. The prescribing information does not specifically warn about gastroparesis, which may support claims of inadequate warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.